Cure My Disease

Don't miss your cure!

 Log in / Sign up

RNA vaccine aims to control HIV without daily pills

NCT ID NCT07698600

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests an experimental RNA-based vaccine called BNT168 in adults both with and without HIV. The goal is to see if the vaccine is safe, triggers an immune response, and can help control the amount of virus in the body. Participants receive either the vaccine or a placebo injection. The trial is early-stage and focuses on safety and immune markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BNT168 (RNA-based vaccine)
What this could lead to
If successful, this vaccine could help control HIV virus levels without daily medication, potentially reducing the need for lifelong antiretroviral therapy.
What could go wrong
This is an early phase 1/2 trial with only 126 participants, so results may not apply broadly. The vaccine may not trigger a strong enough immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV -1 INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.